Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: GHRH in Aging and MCI
NCT00257712Phase 2Completed
- Sponsor
- University of Washington
- Start
- Feb 2006
- Primary completion
- Dec 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tesamorelin in Mild Cognitive Impairment (MCI) (2 arms), sponsored by University of Washington. Primary endpoint: Change in declarative memory at 30 weeks. Started Feb 2006; status: completed.
02
Drugs
tesamorelin
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00257712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257712.